Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2007 Sep;56(9):1181-3.
doi: 10.1136/gut.2006.115980.

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Stephen B Hanauer  1
Affiliations
Comment

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Stephen B Hanauer. Gut. 2007 Sep.

Abstract

Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vermeire S, Noman M, van Assche G.et al The effectiveness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in Crohn's disease. Gut 2007561226–1231. - PMC - PubMed
    1. Schreiber S, Rutgeerts P, Fedorak R N.et al A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005129807–818. - PubMed
    1. Hanauer S, Lukas M, Macintosh D.et al A randomized, double‐blind, placebo‐controlled trial of the human anti‐TNF‐alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease [abstract]. Gastroenterology 2004127332
    1. Targan S R, Hanauer S B, van Deventer S J.et al A short‐term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 19973371029–1035. - PubMed
    1. Colombel J F, Sandborn W J, Rutgeerts P.et al Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial. Gastroenterology 200713252–65. - PubMed

MeSH terms